Instrument Inactif

Autres langues AVEO Pharmaceuticals, Inc.

Actions

AVEO

US0535883070

Produits pharmaceutiques

Autres langues

22/07	Arcus Biosciences Announces Clinical Supply Agreement with Aveo Oncology to Evaluate Casdatifan in Combination with Tivozanib for Advanced Kidney Cancer Patients
30/06	AVEO Pharmaceuticals, Inc. Announces Executive Changes
30/06	AVEO Pharmaceuticals, Inc. Announces CEO Changes
18/02	AVEO Oncology Announces Completion of the First Interim Analysis in the Global Phase 3 FIERCE-HN Study
14/01	AVEO Oncology Announces First Patient Dosed in Front-Line AML Combination Study of Ficlatuzumab
18/02/25	AVEO Oncology Presents Two Posters for Tivozanib at the 2025 ASCO GU Meeting
16/09/24	AVEO Pharmaceuticals, Inc. Presents TiNivo-2 Results and TIVO-3 Exploratory Post Immunotherapy Survival Analysis at ESMO 2024
18/07/24	Aveo Oncology Announces Phase 3 Renal Cell Carcinoma Clinical Trial (TiNivo-2) Results
13/06/24	LG Chem Company and AVEO Oncology Announce LG Chem's First Proprietary Anti-Cancer Compound Enters Phase 1 Clinical Study, Dosing Initiated in the U.S
25/03/24	AVEO Pharmaceuticals, Inc. Announces Executive Changes
06/02/24	Aveo Oncology Announces Publication of Long-Term Survival in Patients with Relapsed/Refractory Advanced Renal Cell Carcinoma Treated with Tivozanib: Analysis of the Phase Iii Tivo-3 Trial in the Oncologist
16/01/24	AVEO Oncology Enrolls First Patient in Pivotal FIERCE-HN Clinical Trial to Evaluate Ficlatuzumab in Combination with ERBITUX® in Patients with HPV-negative Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
27/06/23	AVEO Oncology Announces Completion of Enrollment in Pivotal Phase 3 TiNivo-2 Study of FOTIVDA(R) in Combination with OPDIVO(R) in Advanced Renal Cell Carcinoma
20/01/23	South Korean Stocks Climb on Demand Recovery Hopes from China; LG Chem Stocks Add 1%
20/01/23	AVEO Completes Acquisition by LG Chem
20/01/23	LG Chem Acquires US Biopharma Firm AVEO Pharmaceuticals
19/01/23	AVEO PHARMACEUTICALS, INC. : Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)
19/01/23	AVEO Pharmaceuticals, Inc. Announces Management Changes
19/01/23	LG Chem Completes Acquisition of AVEO Oncology
19/01/23	AVEO Oncology Appoints Martin Birkhofer as Its Chief Medical Officer
19/01/23	AVEO Pharmaceuticals, Inc.(NasdaqCM:AVEO) dropped from NASDAQ Composite Index
19/01/23	AVEO Pharmaceuticals, Inc.(NasdaqCM:AVEO) dropped from S&P Global BMI Index
19/01/23	AVEO Pharmaceuticals, Inc.(NasdaqCM:AVEO) dropped from S&P TMI Index
19/01/23	LG Chem, Ltd. completed the acquisition of AVEO Pharmaceuticals, Inc. from a group of shareholders.
18/01/23	AVEO Pharmaceuticals Receives CFIUS Clearance for LG Chem Merger